EGFR-Targeting PROTAC Compounds for Resistant Mutation Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EGFR-targeting PROTACs are ineffective in degrading all major EGFR mutations, such as Del19, L858R, Del19/T790M, L858R/T790M, and L858R/T790M/C797S, necessitating the development of compounds that can overcome drug resistance in non-small cell lung cancer.
Innovation Solution
Novel bifunctional compounds are conjugated with EGFR inhibitor moieties and E3 ligase ligands to recruit targeted proteins to E3 ubiquitin ligase for degradation, utilizing specific chemical structures to address EGFR mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional EGFR inhibitors are used, then EGFR enzymatic activity is inhibited, but drug resistance develops through mutations such as T790M and C797S
Solution Approach 1:
The patent employs PROTAC molecules as intermediary agents that facilitate the degradation of EGFR mutant proteins. Instead of directly inhibiting EGFR enzymatic activity, the PROTAC acts as a mediator that recruits E3 ubiquitin ligase to the target protein, leading to its degradation via the ubiquitin-proteasome pathway. This intermediary mechanism overcomes resistance mutations by eliminating the target protein rather than competing with mutated binding sites.
Solution Approach 2:
The patent utilizes bifunctional compounds with specific structural parameters designed to bind both the EGFR inhibitor moiety and the E3 ligase ligand moiety. By optimizing parameters such as the linker length (L1-L6), substituent groups (R1-R14), and molecular weight, the PROTAC achieves effective degradation of various EGFR mutants including Del19, L858R, and C797S-resistant forms.
2Reliability
If EGFR-targeting PROTACs are designed to degrade specific mutants, then efficacy against those mutants improves, but broad-spectrum coverage of all major EGFR mutations is lost
Solution Approach 1:
The patent designs PROTAC molecules with universal binding characteristics that enable them to degrade multiple EGFR mutation types simultaneously. The EGFR inhibitor moiety is selected to maintain affinity across different mutant forms, while the E3 ligase ligand moiety ensures consistent recruitment of the degradation machinery. This multi-functional design allows a single PROTAC compound to address Del19, L858R, T790M, and C797S mutations.
Solution Approach 2:
The patent employs dynamic molecular structures that can adapt to different EGFR mutant conformations. The flexible linker regions and substituent groups allow the PROTAC to adjust its binding mode to accommodate structural variations among different EGFR mutants, thereby maintaining degradation efficacy across multiple mutation types.
3Reliability
If bifunctional PROTAC compounds are constructed with multiple moieties, then degradation capability is enhanced, but molecular complexity and synthesis difficulty increase
Solution Approach 1:
The patent divides the PROTAC molecule into distinct functional segments: an EGFR inhibitor moiety, a linker region (L1-L6), and an E3 ligase ligand moiety. Each segment is independently optimized for its specific function, allowing for modular design and simplified synthesis. The linker acts as a separable connector that can be adjusted without redesigning the entire molecule.
Solution Approach 2:
The patent extracts the essential degradation function from complex multi-component systems by focusing on the core PROTAC structure consisting of only two necessary binding domains connected by a flexible linker. This extraction eliminates unnecessary molecular complexity while preserving the ubiquitin-proteasome pathway activation mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively degrade various EGFR mutations, providing a therapeutic strategy to overcome drug resistance in non-small cell lung cancer.
Implementation Method 1
Ubiquitin ligases, also called an E3 ubiquitin ligase, directly catalyze the transfer of ubiquitin from the E2 to the target protein for degradation
Implementation Method 2
Proteasomes are protein complexes which degrade unneeded, misfolded or abnormal proteins into small peptides to maintain health and productivity of the cells
Data Source
AI summary
Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.